APLM
APLM clinical trials: Apollomics Inc.
Every trial on ClinicalTrials.gov where Apollomics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 7
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
APLM on the catalyst calendar · APLM registry changes
- Primary completion Oct 31, 2028Sponsor estimatePhase 1NCT05055518APL-102 Capsule in Patients With Advanced Solid TumorsApollomics Inc. · Advanced Solid TumorSuspendedAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2024ActualPhase 3NCT05054543Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLApollomics Inc. · Relapsed/Refractory AMLTerminatedAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 28, 2024ActualPhase 1NCT04839341Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML PatientsApollomics Inc. · Relapsed/Refractory AMLCompletedAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2026Sponsor estimatePhase 2NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsApollomics Inc. · Solid TumorsRecruitingAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2022Sponsor estimatePhase 1NCT05367388A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsApollomics Inc. · BioequivalenceUnknown statusAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2022ActualPhase 1NCT03053466APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsApollomics (Australia) Pty. Ltd. · Solid TumorCompletedAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2021ActualPhase 1/Phase 2NCT03655613APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCApollomics (Australia) Pty. Ltd. · Hepatocellular CarcinomaTerminatedAPLMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1/Phase 2NCT04743505Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer...Washington University School of Medicine · Metastatic Non Small Cell Lung CancerActive, not recruitingAPLMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner